Core Viewpoint - The company announced that executive Zhao Zhenping has reduced his shareholding by selling 62,500 shares, which represents 0.02% of the total share capital, due to personal financial needs [1] Summary by Relevant Sections - **Share Reduction Details** - The share reduction took place from November 4, 2025, to November 25, 2025 [1] - The selling price ranged from 22.00 to 23.50 yuan per share [1] - The total amount raised from the share reduction was 1.4163 million yuan [1] - **Compliance with Previous Plans** - The actual reduction aligns with the previously disclosed reduction plan, confirming that the plan has been fully executed [1]

Core Viewpoint - Aorite Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of a combined packaging of estradiol tablets and estradiol/dydrogesterone tablets, which is expected to enhance the company's market competitiveness and positively impact its operating performance [1][5][6]. Group 1: Drug Registration Information - The drug is named estradiol tablets/estradiol/dydrogesterone tablets combined packaging, with a registration number of 2025S03486 [1]. - The formulation includes estradiol 2mg and dydrogesterone 10mg [1]. - The drug is classified as a Class 4 chemical drug and is produced by Aorite's subsidiary, Yangzhou Aorite Pharmaceutical Co., Ltd. [1][2]. Group 2: Market Situation - The drug is indicated for the treatment of menopausal syndrome caused by natural or surgical menopause [2]. - The drug was originally developed by Abbott B.V. and was approved for domestic sale in 2015 under the brand name "Fentam." [3]. - As of now, there are two companies, Abbott and Yangzhou Aorite, that have passed the consistency evaluation for this drug in China [3]. Group 3: Financial Investment - As of October 31, 2025, the company has invested approximately 12.64 million RMB in the research and development of this drug [4]. - The hospital sales revenue for "Fentam" is projected to be 564 million RMB in 2024 [4]. Group 4: Impact on Company - The approval of the drug registration is expected to enhance the company's competitiveness in the pharmaceutical market [5]. - The new product's market entry is anticipated to have a positive effect on the company's financial performance [5].

Group 1 - The core point of the article is that Aorite has received a drug registration certificate for a combined packaging of estradiol tablets and estradiol/dydrogesterone tablets from the National Medical Products Administration [2] Group 2 - Aorite's wholly-owned subsidiary, Yangzhou Aorite Pharmaceutical Co., Ltd., is the entity that received the approval [2]

Core Viewpoint - Aorite (605116.SH) has received approval from the National Medical Products Administration for the registration of a combined packaging of estradiol tablets and dydrogesterone tablets, which is expected to enhance the company's market competitiveness and positively impact its operating performance [1] Group 1 - Aorite's wholly-owned subsidiary, Yangzhou Aorite, has been granted a drug registration certificate for the combined packaging of estradiol tablets and dydrogesterone tablets [1] - The drug, developed by Abbott B.V., is intended for the treatment of menopausal syndrome caused by natural or surgical menopause [1] - The combined packaging was initially approved for import in 2015 under the brand name "Feminine" [1] Group 2 - The new drug registration is classified under the new registration method for chemical drugs, which is expected to improve the company's competitive position in the pharmaceutical market [1] - The approval of this product for domestic sales is anticipated to have a positive effect on the company's financial performance [1]

Core Viewpoint - The company, Aorite (605116.SH), has received approval from the National Medical Products Administration for a combined packaging of estradiol tablets and estradiol-dydrogesterone tablets, which is expected to enhance its market competitiveness and positively impact its financial performance [1]. Group 1 - Aorite's wholly-owned subsidiary, Yangzhou Aorite Pharmaceutical Co., Ltd., has obtained a drug registration certificate for the combined packaging of estradiol tablets and estradiol-dydrogesterone tablets [1]. - The approved product is intended for the treatment of perimenopausal syndrome caused by natural or surgical menopause [1]. - The registration of the product under the new classification method for chemical drugs is expected to improve the company's market position in this therapeutic area [1].

Group 1 - The core point of the article is that Aorite Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for a new drug registration certificate for a combination packaging of estradiol tablets and estradiol-dydrogesterone tablets [1] - Aorite's revenue composition for the first half of 2025 is as follows: 85.12% from self-produced raw materials and intermediates, 11.64% from formulations, 2.74% from trade, and 0.5% from other businesses [1] - As of the report date, Aorite's market capitalization is 8.9 billion yuan [1] Group 2 - The article also mentions that another company, identified by its stock code 688496, is under investigation by the China Securities Regulatory Commission due to a significant loss exceeding 100 million yuan shortly after its IPO, with its main customer reducing purchases [1]

Core Viewpoint - Aorite (605116.SH) announced that its wholly-owned subsidiary, Yangzhou Aorite Pharmaceutical Co., Ltd., received a drug registration certificate from the National Medical Products Administration for a combination packaging of estradiol tablets and estradiol/dydrogesterone tablets, which is intended for the treatment of perimenopausal syndrome caused by natural or surgical menopause [1] Group 1 - The newly approved product, branded as "Aoshutong," is classified under the new registration category for chemical drugs, which enhances the company's market competitiveness in this pharmaceutical area [1] - The approval of this product is expected to have a positive impact on the company's operational performance due to its anticipated domestic market launch [1]

证券代码：605116 证券简称：奥锐特 公告编号：2025-084 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 注册分类：化学药品4类 上市许可持有人：扬州奥锐特药业有限公司 关于全资子公司获得药品注册批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，奥锐特药业股份有限公司（以下简称"奥锐特"或"公司"）全资子 公司扬州奥锐特药业有限公司（以下简称"扬州奥锐特"）收到国家药品监督管 理局（以下简称"国家药监局"）核准签发的一份雌二醇片/雌二醇地屈孕酮片复 合包装（以下简称"该药品"）《药品注册证书》，现将相关情况公告如下： 一、注册证书基本信息 药品名称：雌二醇片/雌二醇地屈孕酮片复合包装 批件号：【2025S03486】 剂型：片剂 规格：雌二醇片含雌二醇2mg；雌二醇地屈孕酮片含雌二醇2mg和地屈孕酮 10mg 申请事项：药品注册（境内生产） 药品生产企业：扬州奥锐特药业有限公司 药品批准文号：国药准字H20256016 审评结论：根据《中华人民共和国药品管理法》及有关规定，经审查 ...

智通财经APP讯，奥锐特(605116.SH)发布公告，近日，公司全资子公司扬州奥锐特药业有限公司(简 称"扬州奥锐特")收到国家药品监督管理局核准签发的一份雌二醇片/雌二醇地屈孕酮片复合包装《药品 注册证书》。该药品用于治疗自然或术后绝经所致的围绝经期综合征。 本次扬州奥锐特的雌二醇片/雌二醇地屈孕酮片复合包装(注册商标"奥舒桐")按照化学药品新注册分类方 法获得药品注册批件，有利于提升公司在该药品领域的市场竞争力，同时新批准产品在国内上市销售， 有望对公司经营业绩产生积极影响。 ...

格隆汇11月21日丨奥锐特(605116.SH)公布，自2025年11月1日至2025年11月21日，公司通过上海证券交 易所交易系统以集中竞价交易方式已累计回购公司股份222.47万股，占公司目前总股本的比例为 0.55%，回购成交的最高价为22.59元/股，最低价为18.83元/股，支付的资金总额为人民币4623.11万元 （不含交易费用）。 ...